688073.SHG Bide Pharmatech Co. Ltd. A
- Market cap
- CNY 6.36B
- P/E
- 27.6x
- P/B
- 2.74x
- ROE
- 10.0%
- Dividend yield
- 1.25%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688073.SHG undervalued?
Graham number688073.SHG trades 83.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bide Pharmatech Co. Ltd. A fundamental analysis
No fundamental analysis for Bide Pharmatech Co. Ltd. A yet.
Bide Pharmatech Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bide Pharmatech Co. Ltd. A
Bide Pharmatech Co., Ltd. engages in the research, development, production, and sale of drug molecule building blocks and scientific reagents in China. Its products are used in life sciences, organic chemistry, analytical chemistry, and other applications. Bide Pharmatech Co., Ltd. was founded in 2007 and is based in Shanghai, China.
Full company profileBide Pharmatech Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bide Pharmatech Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 391M | 606M | 834M | 1.09B | 1.10B | 1.32B | 1.37B |
| Gross Profit | 213M | 300M | 370M | 437M | 455M | 590M | 689M |
| Operating Income | 91.5M | 124M | 166M | 129M | 159M | 242M | 349M |
| EBITDA | - | - | 192M | 155M | 180M | 232M | 278M |
| Net Income | 59.0M | 97.6M | 146M | 110M | 117M | 152M | 207M |
| EPS | 0.94 | 1.43 | 1.61 | 1.21 | 1.29 | 1.67 | 2.27 |
| Balance Sheet | |||||||
| Total Assets | 532M | 906M | 2.36B | 2.42B | 2.42B | 2.52B | 2.49B |
| Total Liabilities | 168M | 277M | 283M | 325M | 391M | 471M | 428M |
| Shareholders' Equity | 364M | 629M | 2.08B | 2.09B | 2.03B | 2.05B | 2.06B |
| Cash & Short-term Investments | 91.4M | 193M | 1.51B | 1.27B | 1.11B | 941M | 842M |
| Cash Flow | |||||||
| Operating Cash Flow | 3.65M | -64.9M | 29.9M | -57.4M | 158M | 28.3M | - |
| Capital Expenditure | 37.7M | 29.2M | 38.4M | 61.1M | 88.3M | 24.3M | 7.80M |
| Free Cash Flow | -34.1M | -94.1M | -8.54M | -118M | 70.0M | 4.04M | 175M |
| Ratios | |||||||
| ROE | 16.2% | 15.5% | 7.0% | 5.2% | 5.8% | 7.4% | 10.0% |
| ROA | 11.1% | 10.8% | 6.2% | 4.5% | 4.9% | 6.0% | 8.3% |
| Net Profit Margin | 15.1% | 16.1% | 17.5% | 10.0% | 10.7% | 11.5% | 15.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bide Pharmatech Co. Ltd. A dividends
- Dividend yield
- 1.25%
- Forward dividend
- 1.16 CNY
- Payout ratio
- 52.6%
- Ex-dividend date
- Jun 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 79.8M | 0.88 | 52.6% |
| 2024 | CNY 79.9M | 0.88 | 68.0% |
| 2023 | CNY 100M | 1.10 | 91.3% |
| 2022 | CNY 83.6K | 0.00 | 0.1% |
| 2021 | CNY 188K | 0.00 | 0.2% |
| 2020 | CNY 23.9M | 0.38 | 40.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on May 25, 2023.
Who owns Bide Pharmatech Co. Ltd. A
- Insiders 58.66%
- Institutions 7.31%
- Public & others 34.03%
- Shares outstanding 90.9M
- Free float 33.2M
Bide Pharmatech Co. Ltd. A company profile
- Company name
- Bide Pharmatech Co. Ltd. A
- Ticker
- 688073.SHG
- ISIN
- CNE100005NV3
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 734
- Fiscal year end
- December
- Address
- Building 3, Shanghai, China, 200433
- Phone
- 86 21 6162 9020
- Website
- bidepharm.com
About Bide Pharmatech Co. Ltd. A
Bide Pharmatech Co., Ltd. engages in the research, development, production, and sale of drug molecule building blocks and scientific reagents in China. Its products are used in life sciences, organic chemistry, analytical chemistry, and other applications. Bide Pharmatech Co., Ltd. was founded in 2007 and is based in Shanghai, China.
Bide Pharmatech Co. Ltd. A management
4- Ms. Lan DaiGM & Chairman · born 1972
- Kun WangCFO & Accounting Supervisor
- Xuan WangBoard Secretary · born 1985
- Ms. Weiqing LuCore technical personnel · born 1986